- Fate Therapeutics, Inc. (NASDAQ: FATE) is a clinical-stage biopharmaceutical company focused on developing first-in-class, induced pluripotent stem cell (iPSC)-derived cellular immunotherapies for cancer and autoimmune diseases.
- In 2026, the company presented preclinical data for its next-generation off-the-shelf CAR T-cell product candidate, FT839, at the American Association for Cancer Research Annual Meeting, and reported significant clinical progress with FT819 and FT836 in treating autoimmune diseases and solid tumors.
- Fate Therapeutics has expanded its Phase 1 enrollment for FT819 across 16 clinical sites in the U.S., U.K., and EU, with notable early activity observed in patients with systemic lupus erythematosus and colorectal cancer.
- The ideal buyer for Fate Therapeutics includes healthcare providers and institutions looking for innovative CAR T-cell therapies that offer outpatient treatment options and improved patient outcomes, addressing the need for effective and accessible cancer and autoimmune disease therapies.
Engineering is the largest team with 104 employees, representing about 43% of the company’s workforce. Operations (28) and Business Management (28) form sizable portions of the organization, while specialized groups in Healthcare (19) and Quality (16) support development and compliance needs. Corporate functions include Finance and Administration (14), Information Technology (7), Human Resources (7), and Risk, Safety, Compliance (6). An additional 15 employees are categorized as Other, reflecting roles that span multiple disciplines or niche specialties.
Fate Therapeutics’ workforce is primarily based in San Diego, CA with 173 employees, accounting for roughly 71% of total headcount. Additional presence includes Los Angeles, CA (6), San Francisco, CA (6), Carlsbad, CA (4), Poway, CA (3), and smaller teams in Raleigh, NC (2), Sunnyvale, CA (2), Cambridge, MA (2), and Chula Vista, CA (2). A further 44 employees are distributed across other locations, which likely includes additional sites and remote roles. This footprint reflects a California-centered organization with select satellite teams across the U.S.
